- Previous Close
23.40 - Open
23.60 - Bid 23.60 x --
- Ask 24.00 x --
- Day's Range
23.60 - 23.60 - 52 Week Range
13.10 - 24.00 - Volume
180 - Avg. Volume
3 - Market Cap (intraday)
2.97B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-0.25 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.00
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services. In addition, the company offers Olink normalized protein expression (NPX) data processing software, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics. It sells its products and services through its own direct sales force in Sweden, the United States, rest of the Americas, rest of Europe, the Middle East, Africa, Japan, and internationally. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. Olink Holding AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
www.olink.com707
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 6XA.F
View MorePerformance Overview: 6XA.F
Trailing total returns as of 6/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6XA.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6XA.F
View MoreValuation Measures
Market Cap
2.94B
Enterprise Value
2.87B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.18
Price/Book (mrq)
6.73
Enterprise Value/Revenue
17.92
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-19.72%
Return on Assets (ttm)
-6.56%
Return on Equity (ttm)
-7.03%
Revenue (ttm)
170.89M
Net Income Avi to Common (ttm)
-33.7M
Diluted EPS (ttm)
-0.25
Balance Sheet and Cash Flow
Total Cash (mrq)
109.28M
Total Debt/Equity (mrq)
5.68%
Levered Free Cash Flow (ttm)
-41.41M